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SUMMARY
Aim: To explore the efficacy and safety of the topically
acting steroid beclometasone dipropionate (BDP) in an
oral controlled release formulation in the treatment of
extensive or left-sided ulcerative colitis.
Methods: In a multicentre, randomised, parallel-group,
single-blind study, patients with active mild to moderate
ulcerative colitis were randomised to a 4-week treat-
ment with BDP 5 mg/day o.d. vs. 5-ASA 0.8 g t.d.s. The
primary efficacy variable was the decrease of Disease
Activity Index (DAI) (clinical symptoms and endoscopic
appearance of mucosa). Safety was evaluated by
monitoring adverse events, vital signs, haematochem-
ical parameters and adrenal function.
Results: One hundred and seventy-seven patients were
enrolled and randomly treated with BDP (n ¼ 90) or
5-ASA (n ¼ 87). Mean DAI score decreased in both
treatments groups (P < 0.0001 vs. baseline for both
groups). Clinical remission was achieved in 63.0% of
patients in the BDP group vs. 62.5% in the 5-ASA
group. A significant DAI score improvement (P < 0.05)
in favour of BDP was observed in patients with
extensive disease. Both treatments were well tolerated.
Mean plasma cortisol levels were significantly reduced
vs. baseline in BDP recipients, but without signs of
pituitary–adrenal function depletion.
Conclusion: Oral BDP gave an overall treatment result in
patients with active ulcerative colitis without signs of
systemic side-effects.
INTRODUCTION
Approximately 95% of all incident cases of ulcerative
colitis are mild or moderate in severity, and most patients
have an endoscopic involvement distal to the splenic
flexure,1 although proximal extension is not uncommon
and should be considered if the clinical pattern worsens.2
The aminosalicylic acid derivatives of sulfasalazine have
a fundamental role in the treatment of mild or moderate
ulcerative colitis, and oral formulations are effective for
both proximal and distal colitis.3, 4
Corticosteroids (CS) have been widely used for the
treatment of inflammatory bowel diseases for over
40 years because of their potent anti-inflammatory
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activity and their interference with immunological
responses,5, 6 but the therapeutic benefits are compro-
mised by an extensive spectrum of side-effects and a
negative impact on quality of life. For this reason, the
past decade was characterised by the introduction of
topically acting corticosteroids with a more favourable
safety profile, such as tixocortol pivalate, budesonide
and beclometasone dipropionate (BDP). These topically
acting corticosteroids are characterised by a prompt and
potent anti-inflammatory activity and a low systemic
bioavailability, which is mainly achieved through an
extensive first-pass metabolism.7 These newer com-
pounds provide advantages over the older systemic
corticosteroids by minimising the occurrence of the
adverse effects typical of this drug class, whilst achiev-
ing equivalent, or even superior efficacy.8
At first developed for the treatment of asthma and
allergic rhinitis, BDP has been formulated into rectal
suspension enema and more recently into oral delayed-
release preparations for the treatment of patients with
ulcerative colitis. The rectal formulation of BDP has
been found to be beneficial in the treatment of active
distal ulcerative colitis, with an efficacy comparable to
that of conventional corticosteroids or aminosalicylates,
from the results of controlled studies vs. hydrocortisone,
prednisolone or betamethasone phosphate9–13 and
comparative studies vs. mesalazine (5-aminosalicylic
acid; 5-ASA).14, 15
The oral controlled release formulation of BDP is
constituted by a gastro-resistant methacrylate film
coating (Eudragit L100/55) that prevents the tablets
from dissolving in the stomach and a modified release
core of hydroxypropyl methylcellulose (Methocel K4M)
that dissolves at pH values lower than 6.0. In this way
the drug is released in the distal small bowel and
throughout the passage of the colon, as demonstrated
by in vivo gamma scintigraphy technique to evaluate
gastrointestinal transit and release of oral BDP.16 Oral
BDP could be considered similar to the controlled ileal
release formulation of recently launched Budesonide for
the treatment of active ileocaecal Crohn’s disease, in
which the drug is released at a pH above 5.5, and
50–80% of an oral dose is absorbed in the ileum and
proximal colon.17
The aim of the present study was to explore the efficacy
and safety of oral BDP in the treatment of extensive or
left-sided acute symptomatic ulcerative colitis and
compare it with an established treatment such as oral
delayed-release 5-ASA.
METHODS
Patients
The main criterion for inclusion was a definite diagnosis
of extensive or left-sided mild to moderately active
ulcerative colitis. Out-patients of either sex, aged
18–70 years, who satisfied these criteria and had a
Disease Activity Index (DAI) score > 3 and < 10 were
eligible for enrolment.18 DAI is a 12-point scoring
system which includes clinical (stool frequency, rectal
bleeding and physician’s assessment of disease severity)
and endoscopic (mucosal appearance) parameters
(Table 1). Patients with a DAI score < 3 were
considered in clinical remission, 3–6 in mild, 7–10 in
moderate, and > 10 in severe activity of the disease.19
Exclusion criteria were: severe ulcerative colitis or
clinical remission on the basis of DAI score, severe renal,
liver or heart failure, diabetes mellitus, active gastrodu-
odenal ulcer, osteoporosis, severe or moderate hyper-
tension, neoplastic disease, psychotic disorders, drug or
substance abuse disorder, known hypersensitivity to
corticosteroids or aminosalicylates, pregnancy and lac-
tation. Patients undergoing treatment with corticoster-
oid medications, 5-ASA or sulfasalazine for at least one
Table 1. Disease Activity Index (DAI)
Score
Stool frequency (daily average)
Normal 0
1–2 Stools/day > normal 1
3–4 Stools/day > normal 2
> 4 Stools/day > normal 3
Rectal bleeding
None 0
Streaks of blood 1
Obvious blood 2
Mostly blood 3
Mucosal appearance
Normal 0
Mild friability 1
Moderate friability 2
Exudation, spontaneous bleeding 3
Physician’s rating of disease activity
Normal 0
Mild 1
Moderate 2
Severe 3
Maximum score ¼ 12.
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month prior to enrolment were excluded, and the use of
these agents as concomitant treatments during the
study period was not allowed. In case of bacterial or
viral infections, other than those affecting the gastro-
intestinal tract, treatment with antibacterial drugs was
allowed, as well as long-standing therapies for concom-
itant diseases unrelated to ulcerative colitis (i.e. hyper-
tension).
This study was conducted in accordance with the
Declaration of Helsinki and was approved by local Ethic
Committees. All patients provided written informed
consent before entry.
Study drugs
Chiesi Farmaceutici S.p.A. (Parma, Italy) supplied both
BDP 5 mg tablets and 5-ASA 400 mg tablets (Asacol
400 mg tablets; Bracco S.p.A., Italy). Patients were
randomly assigned to receive one tablet of BDP 5 mg/
day (once daily early in the morning) or six tablets of
5-ASA 400 mg per day (two tablets early in the
morning, two tablets at lunchtime and two tablets in
the evening) for 4 weeks.
Study design
This study was performed according to a multicentre,
single blind, randomised and controlled design. Due to
the technical difficulties of performing a study with a
double-blind, double-dummy design, the third-part
blind observer method was used to assess the efficacy
of the test treatments. In order to ensure unbiased
efficacy assessments, the investigators who performed
endoscopic and histological examinations and the
evaluation of the clinical symptoms of ulcerative colitis
were blinded to patients’ treatment assignment,
whereas the investigators in charge of treatment
allocation were excluded from all efficacy assessments.
At each participating centre, treatment allocation was
made from blocks of four numbers produced by a
computer-generated randomisation list (SAS software,
version 6.08). The investigators who had assigned the
test treatments checked compliance at each visit by
counting residual study medication.
Experimental procedures
During the screening visit (Visit 1), the eligible patients
provided a written informed consent. The medical
history of each one was collected, and a complete
clinical evaluation to determine vital signs (heart rate,
systolic and diastolic blood pressure), body weight and
clinical parameters of ulcerative colitis (stool frequency,
blood in stools, general health conditions) was per-
formed.
All patients were graded with clinical findings and
underwent to a pancolonoscopy to determine activity
and extension of the disease and to obtain tissue for
histopathology during the baseline visit (5–10 days
after the screening visit, Visit 2) and at the end of the
4-week treatment period (Visit 4). Endoscopic activity
was graded according to Baron’s criteria.20 Mucosal
biopsy specimens were obtained from each segment of
the colon (ascending, transverse, descending and sig-
moid) and rectum to establish the histologic activity of
ulcerative colitis. The degree of inflammation in the
histological specimens was graded according to the
criteria of Truelove and Richard.21 A complete haemat-
ochemical evaluation, including erythrocyte count
(RBC), white blood cell count (WBC), platelet count, urea
nitrogen, plasma glucose, creatinine, alanine amino-
transferase, aspartate aminotransferase, sodium, potas-
sium, erythrocyte sedimentation rate (ESR), C-reactive
protein (CRP), total and fractionated serum proteins and
plasma cortisol, was carried out in each patient at
baseline and at the end of the treatment period. All the
included patients returned also after 2 weeks (Visit 3) for
a complete clinical control, for a compliance check and to
receive study medication for the next 2 weeks of treat-
ment. During this visit an endoscopic evaluation could be
performed if thought necessary by the investigators.
Adverse events were recorded throughout the study
period. Blood pressure (BP), heart rate (HR) and body
weight were monitored at each visit. The variation of DAI
according to Sutherland et al. from Visit 2 to Visit 4 was
used as primary efficacy parameter18 (Table 1). The
clinical improvement was defined as a reduction of at
least three points in the DAI score from baseline values
(patients ‘responders’).22
Clinical symptoms of ulcerative colitis other than those
included in the DAI (stool consistency, abdominal pain,
tenesmus and the presence of mucus in stools) (Table 2)
and haematochemical indices of inflammation (ESR,
WBC and CRP) were considered as secondary efficacy
parameters.
The primary safety parameter was the effect of oral
BDP on endogenous cortisol production, which was
evaluated by measuring morning plasma cortisol levels
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and by the monitoring of signs of pituitary–adrenal
function depletion (leg oedema, Cushing-like syndrome,
hypertension, diabetes). Plasma samples were drawn at
08.00–10.00 a.m. following an overnight fast (normal
range 5–25 lg/dL).23
Statistical analysis
The sample size calculation was based on the hypothesis
that after treatment 80% of patients in the BDP group
would be in remission (a DAI score < 3), compared with
60% in the 5-ASA group. With a two-tailed test of
a ¼ 0.05 and 1–b ¼ 0.80, two groups of 80 patients
each were required. Student’s t-test and the Wilcoxon
two-sample test were used to compare the two treat-
ment groups at baseline. The Wilcoxon signed-rank test
was used to compare efficacy outcome measures of the
two groups during the treatment, and the Wilcoxon
two-sample test was used to compare the between-
group changes from baseline to day 28. The distribution
of patients ‘in remission’ and ‘improved’ in the two
treatment groups was compared using the chi-square
test.
All the analyses were conducted on an intention-
to-treat (ITT) basis, and efficacy and safety analyses
were performed on all patients who had received at least
one dose of study medication and who had attended at
least one visit after baseline. Haematochemical and
adrenal function parameters were analysed using
Student’s t-test for paired data and non-paired data
within and between treatments, respectively. As well as
the randomisation list, the statistical analysis was
performed with SAS software, version 6.08. Data are
expressed as mean ± standard error of the mean
(s.e.m.), except when indicated.
RESULTS
A total of 177 patients (90 in the BDP group and 87 in
the 5-ASA group) were randomised to treatment in 13
Italian centres. The groups did not significantly differ for
baseline demographics and disease duration, even if,
despite randomisation, patients with a significantly
higher mean DAI (6.07 vs. 5.31; P < 0.05) were
enrolled in the BDP arm (Table 3). The majority of
ulcerative colitis patients suffered from left-sided disease
extending 25–50 cm (71.8%). However, compared with
the 5-ASA group, the BDP group had a significantly
higher percentage of patients with extensive ulcerative
Table 2. Secondary efficacy variables
Score
Stool consistency
Normal 0
Partially formed 1
Semi-liquid 2
Liquid 3
Abdominal pain
Normal 0
Mild 1
Moderate 2
Severe 3
Tenesmus
Normal 0
Mild 1
Moderate 2
Severe 3
Mucus in stools
None 0
Streaks 1
Obvious 2
Mostly 3
Table 3. Patients’ characteristics
Variables
BDP 5 mg/day
n ¼ 90
5-ASA 2.4 g/day
n ¼ 87 P-value
Sex (M/F), n 57/33 50/37 n.s.
Age (years) 41.1 (1.6) 45.4 (1.5) n.s.
Body weight (kg) 66.6 (1.6) 69.0 (1.2) n.s.
Duration of disease (years) 5.3 (0.5) 5.4 (0.7) n.s.
Patients with left-sided
ulcerative colitis, n (%)
58 (64.4) 69 (79.3) n.s.
Patients with extensive
ulcerative colitis, n (%)
32 (35.6) 18 (20.7) < 0.05
DAI 6.06 (0.20) 5.30 (0.18) < 0.05
Data expressed as a mean (s.e.m.) except when indicated.
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colitis (transverse colon or pancolitis) (35.6% vs. 20.7%;
P < 0.05) (Table 3). Even though the study was
powered for the analysis of all patients, due to the size
of the study subjects with extensive or left-sided forms
were identified post hoc for a further investigation.
Twenty-five patients (14.1%) did not complete the
study: 18 (20%) in the BDP group (eight patients
were lost to follow-up, four patients were non-
compliant, four patients had an insufficient therapeu-
tic response, one patient committed a protocol
deviation and one patient experienced an adverse
event) and seven (8%) in the 5-ASA group (three
patients were non-compliant, two patients were lost to
follow-up, one patient had an insufficient therapeutic
response and one patient experienced a concomitant
disease) (Figure 1). The relevant number of patients
lost to follow-up could have been due both to an
attempt to conduct the study in many centres and the
inclusion of out-patients which, especially in the case
of mild severity of the disease with fast remission of
symptoms, did not return for the following visits.
During the study, only one patient (in the 5-ASA
group) received antibacterial therapy (ampicillin
2 g/day p.o. for 7 days for influenza treatment).
Efficacy evaluation
One hundred and fifty-two patients (72 in the BDP
group and 80 in the 5-ASA group) completed the
treatment period (Figure 1). According to ITT analysis,
the primary efficacy variable DAI was evaluated in 73
patients in the BDP group and 80 patients in the 5-ASA
group: one patient in each group completed the
treatment period, but refused to be submitted to other
endoscopic controls after the baseline visit, and two
patients in the BDP group and one patient in the 5-ASA
group underwent pancolonoscopy after 2 weeks of
treatment at Visit 3, but they later withdrew from the
study because of insufficient therapeutic response.
At the final visit the mean DAI score was significantly
reduced from baseline in both treatment groups: from
6.10 ± 0.20 (median 6, range 3–10) at baseline to
2.44 ± 0.29 (median 2, range 0–11) after treatment in
the BDP group, and from 5.29 ± 0.17 (median 5, range
2–9) to 2.03 ± 0.23 (median 1, range 0–9) in the
5-ASA group (both P < 0.0001 vs. baseline). These
results were also confirmed by the significant improve-
ment starting from the 2-week visit (Visit 3) in both
treatment groups of the single clinical and endoscopic
findings included in the DAI score (stool frequency,
rectal bleeding, physician’s rating of disease activity and
endoscopic appearance of mucosa) [all P < 0.0001 vs.
baseline, except for the physician’s assessment
(P < 0.01 at Visit 3 in both treatment groups)], and
also of the secondary efficacy clinical variables (stool
consistency, abdominal pain, tenesmus and mucus in
stools) (all P < 0.0001 vs. baseline).
The histological assessment confirmed the clinical and
endoscopic findings, with the mean score of Truelove
and Richard decreasing from 1.76 at baseline to 0.93
after treatment in the BDP group, and from 1.62 to 0.90
in the 5-ASA group (P < 0.001 vs. baseline in both
groups). Twenty-three of 70 (32.9%) patients in the
BDP group and 27/77 (35.1%) patients in the 5-ASA
Patients enrolled
n = 177
 BDP 5 mg/day
n = 90 
5-ASA 2.4 g/day 
n = 87 
Withdrawals 
n = 18 
Completed 
n = 72
Withdrawals
n = 7
Completed
n = 80
Insufficient ther. response (4) 
Poor compliance (4) 
Lost to follow-up (8) 
Adverse event (profuse menstrual
bleeding) (1) 
Protocol deviation (1) 
Insufficient ther. response (1) 
Poor compliance (3) 
Lost to follow-up (2) 
Intercurrent disease (1) 
Figure 1. Trial profile.
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group showed histological remission. ESR decreased
significantly from baseline in both groups (from
19.5 ± 1.68 to 15.3 ± 1.62, P < 0.05 in the BDP group
and from 18.0 ± 1.63 to 13.8 ± 1.25, P < 0.01),
reflecting an improvement of the inflammatory status.
No post-treatment changes in WBC or CRP protein were
observed.
The percentages of patients in clinical remission and
with a significant clinical improvement did not signifi-
cantly differ between the two treatment groups, even
when extensive or left-sided colitis were independently
considered (P ¼ n.s. in each case) (Figures 2 and 3).
The results of this study also suggest that patients with
extensive disease were more likely to obtain a better
clinical improvement with BDP compared to 5-ASA. A
significant reduction of the mean DAI score was
achieved in both groups: from 6.50 ± 0.27 (median 7,
range 4–10) to 2.15 ± 0.42 (median 2, range 0–8) in
the BDP group and from 5.78 ± 0.41 (median 6, range
2–8) to 2.67 ± 0.55 (median 2.50, range 0–8) in the
5-ASA group, P < 0.0001), with a significantly lower
mean final DAI score in the BDP group (P < 0.05)
(Figure 3). Moreover, patients suffering from left-
sided ulcerative colitis obtained a significant clinical
improvement in both treatment groups (P < 0.0001) at
the end of study period, with no difference in the final
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Figure 2. Percentage of responders in the BDP group: total
population (n ¼ 73), left-sided ulcerative colitis (n ¼ 47), exten-
sive ulcerative colitis (n ¼ 26).
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Figure 3. Percentage of responders in the 5-ASA group: total
population (n ¼ 80), left-sided ulcerative colitis (n ¼ 62), exten-
sive ulcerative colitis (n ¼ 18).
0 4
0
2
4
6
8
BDP 5 mg/day 5-ASA 2.4 g/day
*
**
*
Weeks
 
M
ea
n 
DA
I s
co
re
Figure 4. Disease Activity Index (DAI) in patients with extensive
ulcerative colitis in the BDP group (n ¼ 26) and in the 5-ASA
group (n ¼ 18). Data expressed as mean ± s.e.m. *P < 0.0001 vs.
baseline. **P < 0.05 between treatments.
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Figure 5. Disease Activity Index (DAI) in patients with left-sided
ulcerative colitis in the BDP group (n ¼ 47) and in the 5-ASA
group (n ¼ 62). Data expressed as mean ± s.e.m. *P < 0.0001 vs.
baseline.
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DAI score between groups (Figures 4 and 5), and with
median values which decreased from 6 (range 3–10) to
2 (range 0–8) in the BDP group and from 5 (range 2–9)
to 1 (range 0–6) in the 5-ASA group.
The single clinical and endoscopic parameters of the
DAI score (stool frequency, rectal bleeding, physician’s
rating of disease activity and mucosal appearance) and
the secondary efficacy clinical variables (stool consis-
tency, abdominal pain, tenesmus and mucus in stools)
were also separately analysed for extensive and left-
sided subgroups, as shown in Table 4 and Table 5. In
extensive forms, the presence of mucus in stools was not
significantly reduced in the 5-ASA group, while all the
other clinical and endoscopic primary and secondary
parameters were statistically improved in both arms at
the end of the study period. The improvement of stool
frequency and consistency, rectal bleeding and abdom-
inal pain started from the 2-week visit (Visit 3) in both
groups, while presence of mucus in stools in the BDP
group, tenesmus in the 5-ASA group and physician’s
assessment of disease severity in both groups were
improved only at the end of the treatment period. In left-
sided forms, apart for the physician’s evaluation [which
was not significantly improved in the BDP group and
Table 4. Effects of treatment with BDP or 5-ASA on DAI single parameters in patients with extensive or left-sided ulcerative colitis
Extensive ulcerative colitis Left-sided ulcerative colitis
Baseline 2 weeks 4 weeks Baseline 2 weeks 4 weeks
BDP 5 mg/day
Stool frequency 2.03 (0.11) 1.23 (0.11)a 0.65 (0.12)a 1.71 (0.10) 1.11 (0.10)a 0.59 (0.10)a
Rectal bleeding 1.53 (0.12) 1.03 (0.13)b 0.31 (0.12)a 1.40 (0.09) 0.87 (0.09)a 0.37 (0.09)a
Physician’s rating of
disease activity
0.81 (0.10) 0.63 (0.11) 0.23 (0.10)c 0.53 (0.08) 0.38 (0.08) 0.17 (0.06)
Mucosal appearance 2.13 (0.11) — 0.96 (0.17)a 2.19 (0.09) — 1.09 (0.14)a
5-ASA 2.4 g/day
Stool frequency 1.61 (0.20) 0.94 (0.13)b 0.83 (0.20)b 1.45 (0.09) 0.83 (0.08)a 0.42 (0.07)a
Rectal bleeding 1.39 (0.18) 0.67 (0.11)c 0.50 (0.15)c 1.33 (0.07) 0.72 (0.08)a 0.32 (0.07)a
Physician’s rating of
disease activity
0.78 (0.13) 0.39 (0.12) 0.33 (0.11)b 0.46 (0.07) 0.37 (0.06) 0.16 (0.05)c
Mucosal appearance 2.00 (0.14) — 1.00 (0.20)c 1.94 (0.08) — 0.89 (0.11)a
Data expressed as mean (s.e.m.).
a P < 0.0001 vs. baseline. b P < 0.01 vs. baseline. c P < 0.001 vs. baseline.
Table 5. Effects of treatment with BDP or 5-ASA on secondary efficacy variables in patients with extensive or left-sided ulcerative colitis
Extensive ulcerative colitis Left-sided ulcerative colitis
Baseline 2 weeks 4 weeks Baseline 2 weeks 4 weeks
BDP 5 mg/day
Stool consistency 1.75 (0.11) 1.13 (0.11)b 0.62 (0.12)a 1.57 (0.08) 0.96 (0.11)a 0.46 (0.09)a
Abdominal pain 1.03 (0.11) 0.47 (0.11)c 0.23 (0.08)a 1.07 (0.10) 0.53 (0.10)a 0.26 (0.08)a
Tenesmus 1.19 (0.12) 0.70 (0.14)b 0.35 (0.16)c 0.93 (0.11) 0.49 (0.09)a 0.22 (0.08)a
Mucus in stools 1.13 (0.11) 0.67 (0.10) 0.38 (0.11)c 1.52 (0.10) 0.87 (0.10)a 0.41 (0.09)a
5-ASA 2.4 g/day
Stool consistency 1.72 (0.16) 0.94 (0.13)c 0.72 (0.18)c 1.38 (0.09) 0.83 (0.09)a 0.37 (0.07)a
Abdominal pain 1.28 (0.14) 0.50 (0.15)c 0.39 (0.16)c 0.94 (0.09) 0.42 (0.08)a 0.19 (0.05)a
Tenesmus 0.72 (0.14) 0.44 (0.15) 0.22 (0.10)b 0.91 (0.10) 0.46 (0.08)a 0.23 (0.06)a
Mucus in stools 0.89 (0.16) 0.56 (0.15) 0.33 (0.14) 1.23 (0.09) 0.63 (0.07)a 0.32 (0.07)a
Data expressed as a mean (s.e.m.).
a P < 0.0001 vs. baseline. b P < 0.01 vs. baseline. c P < 0.001 vs. baseline.
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was improved only at the end of treatment period in the
5-ASA group (P < 0.001)], the 2-week and the 4-week
improvement ratings of all the other clinical and
endoscopic parameters were similar in the two treat-
ment groups.
Safety evaluation
Although they remained within the normal range,
mean morning plasma cortisol levels were statistically
reduced from baseline in the BDP group: 16.13 ± 0.80
to 11.62 ± 0.79 lg/dL at the end of the treatment
period (P < 0.001). In 9/67 (13%) of BDP-treated
patients cortisol levels fell below 5 lg/dL, but these
patients did not show any signs of hypothalamic–
pituitary–adrenal axis (HPA) suppression.
At the end of the treatment period, no clinically
relevant changes in blood pressure, heart rate, body
weight or other haematochemical parameters were
observed in both groups. The incidence of adverse
events was very low in both treatment groups. Only
2/177 (1.1%) of patients experienced adverse events,
which were classified as non-serious: one patient in the
BDP group reported menorrhagia and requested dis-
continuation of the study treatment, and one patient in
the 5-ASA group developed influenza symptoms.
DISCUSSION
Corticosteroids and aminosalicylates are the mainstay of
treatment for ulcerative colitis flare-ups.24–26 Since the
1950s, in which the therapeutic efficacy of cortisone in
the treatment of active ulcerative colitis was first
established,5, 26 systemic corticosteroids such as predn-
isolone have become a standard therapy for moderate
attacks of ulcerative colitis, but important side-effects,
especially those related to interference with adrenal
function, have been described.27 In order to minimise
toxicity, rectal formulations have now largely replaced
systemic therapies in the management of distal coli-
tis.28, 29 However, oral therapies are still required when
the disease extends more proximally.24 Furthermore,
oral formulations are easier to administer (especially
those with the added advantage of once-daily dosing)
and are generally more acceptable to the patients. BDP,
a corticosteroid with topical characteristics,30 has
proven efficacy and good tolerability when administered
as an enema.9–15 This new oral formulation of BDP has
been designed to deliver a powerful anti-inflammatory
effect directly to the site of inflammation (by means of its
high first-pass metabolism and pH-dependent modified-
release system), whilst reducing systemic side-effects
such as Cushing-like syndrome and suppression of the
HPA axis.
After a preliminary dose-finding study showing that
both 5 and 10 mg/day doses have comparable efficacy
but that a 5 mg/day dose is generally better tolerated
and produces fewer inhibitory effects on plasma cortisol
levels,31 it was found useful to treat active ulcerative
colitis with aminosalicylates in conjunction with oral19
or rectal BDP32 in order to obtain a prompt mucosal
inflammation reduction and improve quality of life.
This controlled study was the first in which the efficacy
and safety of oral BDP were assessed in a short-term
therapy of mild to moderate active ulcerative colitis in
comparison with an established treatment such as
delayed-release 5-ASA. The 5-ASA dosage (2.4 g/day,
six tablets per day) was chosen because it lies well within
the accepted therapeutic range (2–4 g/day)3, 33 and has
a treatment duration (4 weeks) that can be considered
sufficient for therapeutic response in patients with this
seriousness of active ulcerative colitis.24 The investiga-
tors who performed all the clinical, endoscopic and
histological evaluations were blinded to treatment
allocation, thus ensuring unbiased assessments, whereas
the fact that the patients were not blinded to their
assigned therapies must be acknowledged as a limitation
of this study. In the absence of a universally accepted
efficacy parameter in ulcerative colitis trials, we used the
widely employed DAI by Sutherland et al.18 as the main
outcome assessment. The two treatment groups were
well balanced for demographic parameters and disease
duration; however, despite randomisation, the BDP arm
included patients with more severe symptoms of active
ulcerative colitis than the compared arm.
Both drugs demonstrated anti-inflammatory effects on
the colon and rectum, which translated into significant
post-treatment clinical, endoscopic and histological
improvement, with similar percentages of patients in
clinical remission in the BDP group (63.0%) compared
with the 5-ASA group (62.5%). Significant differences
in the DAI scores from baseline were also observed in
both treatment groups even considering extensive or
left-sided ulcerative colitis, with patients suffering from
extensive forms of ulcerative colitis (transverse colon
and pancolitis) treated with oral BDP showing to have a
higher probability of achieving a significant clinical and
endoscopic improvement after 4 weeks than patients
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with the same classification of disease treated with oral
5-ASA (P < 0.05 between groups). Histological findings
confirmed the clinical results, with a significant
decrease in Truelove and Richard’s score being achieved
in both groups at the end of the treatment period.
Considering the more severe symptoms of patients
included in the BDP group, the results of oral BDP
administration obtained in this study can be considered
encouraging. The tendency towards a superiority of
once-daily BDP treatment compared with the t.d.s.
administration of oral 5-ASA could be confirmed by a
higher dosage of BDP. The BDP dose used in this study
(5 mg) could have been too low to reach the left or
distal colon in sufficient concentrations, or the release of
the active ingredient might have been too slow. In fact,
the passage of faeces through the distal colon is a fairly
rapid process in the active phase of ulcerative colitis,34
and so the most inflamed parts of the colon might only
have been exposed to the drug intermittently and only
before defecation. These considerations could explain
the better results in patients with extensive disease and
the non-significant difference with the comparative arm
obtained in patients with left-sided ulcerative colitis.
Therefore, studies of the colonic absorption of oral
controlled-release BDP in ulcerative colitis patients are
now in progress to clarify how much of an administered
dose of BDP is actually delivered and absorbed in
different parts of the colon, and if a price in terms of
increased adrenal function suppression and side-effects
could be paid with a higher dosage of 10 mg/day.
As expected, both treatments were well tolerated (14%
patient drop-out), with only one patient in each group
reporting adverse events (menorrhagia in a BDP-treated
patient and influenza symptoms in a 5-ASA recipient);
these were not serious and resolved spontaneously.
Despite a statistically significant reduction from baseline
values, no patients developed symptoms attributable to
HPA axis suppression.
In conclusion, the oral controlled release formulation
of topically active corticosteroid BDP, at a dose of 5 mg/
day, gave an overall disease improvement in patients
with extensive or left-sided, mild to moderately severe
active ulcerative colitis, without clinical signs of sys-
temic side-effects derived from HPA axis suppression.
Owing to the good safety profile shown by oral BDP in
the 4-week treatment of active ulcerative colitis, other
studies are in progress to investigate further the dose–
efficacy ratio and the interference with HPA function
when long-term treatment is suggested.
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